X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2653) 2653
Publication (201) 201
Book Review (60) 60
Newsletter (37) 37
Magazine Article (17) 17
Book Chapter (14) 14
Newspaper Article (10) 10
Conference Proceeding (6) 6
Trade Publication Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
glatiramer acetate (2464) 2464
humans (1750) 1750
multiple sclerosis (1650) 1650
index medicus (1119) 1119
clinical neurology (946) 946
multiple sclerosis - drug therapy (839) 839
female (838) 838
peptides - therapeutic use (749) 749
neurosciences (697) 697
male (669) 669
adult (663) 663
double-blind (584) 584
immunosuppressive agents - therapeutic use (537) 537
animals (501) 501
interferon-beta - therapeutic use (490) 490
multiple sclerosis, relapsing-remitting - drug therapy (455) 455
middle aged (452) 452
neurology (393) 393
placebo-controlled trial (391) 391
experimental autoimmune encephalomyelitis (388) 388
treatment outcome (366) 366
immunology (365) 365
multiple sclerosis - immunology (325) 325
pharmacology & pharmacy (324) 324
interferon-beta (321) 321
interferon beta-1a (318) 318
multiple-sclerosis (306) 306
immunologic factors - therapeutic use (292) 292
disability (288) 288
natalizumab (283) 283
magnetic resonance imaging (277) 277
disease progression (274) 274
multicenter (270) 270
drug therapy (259) 259
adjuvants, immunologic - therapeutic use (258) 258
central-nervous-system (252) 252
interferon beta-1b (251) 251
myelin basic-protein (234) 234
mice (229) 229
therapy (229) 229
care and treatment (226) 226
interferon (219) 219
research (218) 218
interferon beta (216) 216
experimental allergic encephalomyelitis (204) 204
peptides - administration & dosage (194) 194
peptides - pharmacology (194) 194
analysis (192) 192
copolymer 1 (191) 191
medicine & public health (191) 191
peptides - adverse effects (186) 186
multiple sclerosis - therapy (182) 182
t-cells (180) 180
multiple sclerosis - pathology (169) 169
health aspects (160) 160
disease (158) 158
immunosuppressive agents - adverse effects (156) 156
fingolimod (152) 152
immunosuppressive agents - administration & dosage (152) 152
young adult (152) 152
psychiatry (151) 151
multiple sclerosis - physiopathology (150) 150
glatiramer acetate - therapeutic use (147) 147
time factors (147) 147
recurrence (140) 140
multiple sclerosis - diagnosis (139) 139
inflammation (137) 137
adolescent (136) 136
medicine, general & internal (133) 133
disability evaluation (132) 132
relapse rate (130) 130
copaxone (127) 127
immunosuppressive agents - pharmacology (126) 126
neuroprotection (124) 124
immunotherapy (122) 122
t cells (122) 122
clinical trials as topic (121) 121
remitting multiple-sclerosis (121) 121
retrospective studies (119) 119
brain - pathology (118) 118
disease models, animal (114) 114
biological response modifiers (113) 113
progressive multifocal leukoencephalopathy (113) 113
interferon-beta - administration & dosage (110) 110
t-lymphocytes - immunology (110) 110
encephalomyelitis, autoimmune, experimental - immunology (109) 109
dosage and administration (108) 108
clinical trials (106) 106
cytokines (106) 106
encephalomyelitis, autoimmune, experimental - drug therapy (106) 106
immunomodulation (106) 106
mice, inbred c57bl (106) 106
mri (106) 106
regulatory t-cells (106) 106
autoimmunity (104) 104
diagnostic-criteria (103) 103
disease-activity (103) 103
dendritic cells (102) 102
multiple sclerosis, relapsing-remitting - immunology (102) 102
development and progression (99) 99
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2453) 2453
German (70) 70
Spanish (63) 63
Russian (56) 56
French (20) 20
Hungarian (13) 13
Japanese (13) 13
Czech (10) 10
Polish (6) 6
Portuguese (6) 6
Finnish (5) 5
Chinese (4) 4
Italian (4) 4
Serbian (2) 2
Turkish (2) 2
Dutch (1) 1
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Neurology, ISSN 1474-4422, 2008, Volume 7, Issue 10, pp. 903 - 914
Journal Article
Journal Article
CNS Drugs, ISSN 1172-7047, 5/2011, Volume 25, Issue 5, pp. 401 - 414
Journal Article
Journal of the Neurological Sciences, ISSN 0022-510X, 04/2018, Volume 387, pp. 152 - 156
Glatiramer acetate (GA) 40 mg × 3/weekly was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). While the beneficial effect of GA... 
Glatiramer acetate | DTI | Multiple sclerosis | Tract based spatial statistics | MRI | ACCURATE | MECHANISM | ATROPHY | NEUROSCIENCES | BLACK-HOLES | LESIONS | CLINICAL NEUROLOGY | TRIAL | ROBUST | REGISTRATION | BRAIN | Medicine, Experimental | Medical research
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 05/2019, Volume 133, pp. 8 - 14
Complex drugs may be either biological, if the active ingredients are derived from a biological source, or non-biological, if obtained by chemical synthesis.... 
NBCD | Complex drug | Glatiramer | Glatiramoid | MULTICENTER | MULTIPLE-SCLEROSIS | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | EQUIVALENCE | Glatiramer acetate | Generic drugs | Independent regulatory commissions | Chemical synthesis
Journal Article